Vol. 22/No. 21 | OncologyLive

Experts Review Key Data From ESMO Congress 2021

November 29, 2021

Conference Highlights

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

Home Infusion Trend Stirs Debate

November 24, 2021

The COVID-19 pandemic spurred the launching or expansion of in-home cancer therapy infusion programs at several oncology centers around the United States, drawing a surge of interest throughout the field as well as opposition from oncologists who are concerned about the implications for patient safety and the potential impact on community practices that provide in-house infusion services.

Treatment Landscape Shifts Away From Chemotherapy Toward Targeted Approaches in ALL

November 22, 2021

Novel approaches with highly active, minimally toxic agents are needed to improve upon traditional chemotherapy and possibly eliminate chemotherapy altogether in the treatment of patients with acute lymphoblastic leukemia.

Novel ADC Appears to Leverage TROP2 Expression in NSCLC

November 16, 2021

Investigators aim to expand the treatment portfolio with the phase 3 TROPION-LUNG01 trial, which is designed to examine datopotamab deruxtecan vs docetaxel in patients with advanced or metastatic NSCLC without actionable genomic alterations who have previously received platinum-based chemotherapy and immunotherapy. 

Beyond the Peer-Review Publication: Addressing Implications of Research for Patients

November 04, 2021

From the Editor

Maurie Markman, MD, discusses the need for peer-reviewed publications to encourage further discussion and debate, challenge existing ideas or dogma, or provide support for current biological concepts or in the clinical realm for treatment of patients.